Trial Profile
A phase 2, open label, multi-center, controlled, randomized study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine +/- OMV , when administered to healthy infants at 2,4,6 and /or 12 months of age Herts REC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2007
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 09 Mar 2007 New trial record.